KYTHERA BIOPHARMACEUTICALS INC (KYTH) [Rocket]

In millions, except per share items	Dec-31-14	Dec-31-13	Dec-31-12	Dec-31-11	Dec-31-10	Dec-31-09
	10-K	10-K	10-K	10-K	10-K/A	S-1/A
Revenues [+]	132.4	50.5	19.7	13.0	4.5	29.5
Licensing			19.7	13.0	4.5
Revenue growth	162.3%	156.4%	51.6%	189.3%	-84.8%
Cost of goods sold	0.0	0.0	1.9	1.2	0.4	14.8
Gross profit	132.4	50.5	17.8	11.8	4.1	14.8
Gross margin	100.0%	100.0%	90.2%	90.9%	90.8%	50.0%
Selling, general and administrative [+]	31.1	16.1	10.5	6.9	6.8	4.9
General and administrative	31.1	16.1	10.5	6.9	6.8	4.9
Research and development	47.8	34.0	43.2	15.8	14.8	9.8
Other operating expenses	132.4	50.5				14.8
EBITDA [+]	-78.6	-49.8	-35.3	-10.8	-17.4	146.2
EBITDA growth	57.7%	41.2%	227.1%	-37.9%	-111.9%
EBITDA margin	-59.4%	-98.7%	-179.3%	-83.1%	-387.2%	495.7%
Depreciation and amortization	0.3	0.2	0.6	0.1	0.2	161.0
EBIT [+]	-78.9	-50.1	-35.9	-10.8	-17.6	-14.8
EBIT growth	57.6%	39.3%	231.3%	-38.2%	19.0%
EBIT margin	-59.6%	-99.2%	-182.5%	-83.5%	-391.0%	-50.0%
Non-recurring items [+]	52.8
In-process research & development	52.8
Interest expense, net [+]	3.9	1.8	0.4	0.1
Interest expense	4.2	2.0	0.4	0.1
Interest income	0.3	0.1
Other income (expense), net [+]	-0.1		-0.4	-0.2	1.5	0.0
Other					0.9
Pre-tax income	-135.6	-51.9	-36.8	-11.2	-16.0	-14.8
Income taxes	0.0	0.0	0.0	0.0	0.0	0.0
Tax rate	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Net income	-135.6	-51.9	-36.8	-11.2	-16.0	-14.8
Net margin	-102.4%	-102.8%	-186.9%	-85.9%	-357.2%	-50.0%

Basic EPS [+]	($6.04)	($2.71)	($7.47)	($7.98)	($11.64)	($10.85)
Growth	122.7%	-63.7%	-6.3%	-31.5%	7.3%
Diluted EPS [+]	($6.04)	($2.71)	($7.47)	($7.98)	($11.64)	($10.85)
Growth	122.7%	-63.7%	-6.3%	-31.5%	7.3%

Shares outstanding (basic) [+]	22.5	19.2	4.9	1.4	1.4	1.4
Growth	17.3%	288.9%	252.2%	1.5%	1.2%
Shares outstanding (diluted) [+]	22.5	19.2	4.9	1.4	1.4	1.4
Growth	17.3%	288.9%	252.2%	1.5%	1.2%

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.